Article Information
History
- April 11, 2019.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Muhidin K Mahende1,*,
- Eric Huber2,3,
- Elly Kourany-Lefoll4,
- Ali Ali1,
- Brooke Hayward5,
- Deon Bezuidenhout6,
- Wilhelmina Bagchus7,
- Abdunoor M Kabanywanyi1,
- On behalf of the Pediatric Praziquantel Consortium
- 1Ifakara Health Institute, Dar es Salaam, Tanzania
- 2Swiss Tropical and Public Health Institute, Basel, Switzerland
- 3University of Basel, Basel, Switzerland
- 4Ares Trading S.A., Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany
- 5EMD Serono, Inc. Rockland, MA, United States, an affiliate of Merck KGaA, Darmstadt, Germany
- 6Merck (Pty) Ltd, South Africa, an affiliate of Merck KGaA, Darmstadt, Germany
- 7Merck Institute of Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany
- ↵*Corresponding author: mmahende{at}ihi.or.tz Ifakara Health Institute, Off Mwai Kibaki Road Mikocheni, Kiko Avenue Plot No 463, Tanzania.
Posted April 11, 2019.
Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: a randomized, single-blind, crossover study
